Immuno-Oncology Biomarkers

Immuno Oncology biomarkers that can be used to identify inflamed tumors that may help to predict a pre-existing antitumor immune response.To identify the Immuno Oncolocgy biomarkers , clarify this unique interplay between the immune system and the tumor, BMS biomarker research is concentrated on 4 types of areas.They are tumor antigens, inflamed tumor markers, immune suppression markers, and host environment factors. Immuno-Oncology (I-O) biomarkers seeks to characterize the relationship between the immune system, the tumor and its microenvironment, and the host. Unique interactions of these factors, as well as Immuno Oncology  biomarker presence and prevalence, contributes to the balance of activation versus suppression of the antitumor immune response.

  • Biomarkers in Immune monitoring
  • Mutation analysis using Biomarkers to guide therapies
  • Cell proliferation Biomarkers
  • Predictive Biomarkers to immunotherapies
  • Biomarkers in Companion Diagnostics
  • Prognostic Biomarkers
  • Liquid Biopsy for Immuno-Oncology
  • Tumor Neoantigens as Biomarker and target identification
  • Biomarkers for combinational immunotherapies
  • Evaluation of Biomarkers in clinical trials
  • Role of Biomarkers in Cancer Vaccines development
  • Tumor Microenvironment profiling
  • Biomarkers for precision immune-oncology
  • Tumor markers in cancer care

Related Conference of Immuno-Oncology Biomarkers

March 18-19, 2024

5th Global Summit on Oncology and Hematology

Zurich, Switzerland
June 10-11, 2024

8th Global Meeting on Oncology and Radiology

Barcelona, Spain
July 11-12, 2024

24th World Congress on Cancer and Diagnostics

Vancouver, Canada
July 18-19, 2024

14th World Congress on Breast Cancer

Paris, France
September 19-20, 2024

25th World Congress on Cancer Summit

Paris, France

Immuno-Oncology Biomarkers Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in